Bariki Mtafya

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

Martin J. Boeree, Norbert Heinrich, Rob E. Aarnoutse et al. · The Lancet Infectious Diseases · 2016 · 385 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial

Jonny Peter, Lynn S. Zijenah, Duncan Chanda et al. · The Lancet · 2016 · 265 citations

Public Health, Infectious Disease Control, Clinical Medicine +10

Rapid and Accurate Detection of Mycobacterium tuberculosis in Sputum Samples by Cepheid Xpert MTB/RIF Assay—A Clinical Validation Study

Andrea Rachow, Alimuddin Zumla, Norbert Heinrich et al. · PLoS ONE · 2011 · 164 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Increased and Expedited Case Detection by Xpert MTB/RIF Assay in Childhood Tuberculosis: A Prospective Cohort Study

Andrea Rachow, Petra Clowes, Elmar Saathoff et al. · Clinical Infectious Diseases · 2012 · 150 citations · Full text

Public Health, Infectious Diseases, Pediatrics +17

Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay

Wilber Sabiiti, Khalide Azam, Eoghan C. W. Farmer et al. · Thorax · 2020 · 87 citations · Full text

Public Health, Infectious Diseases, Microbiology +17